A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis

For more visit ResearchToPractice.com/5MJCASCOHEME2011
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians and basic scientists sojourn to the American Society of Clinical Oncology (ASCO) Annual Meeting to learn about recent clinical advances that yield alterations in state-of-the-art management for all tumor types. Attracting tens of thousands of attendees from every corner of the globe to both unveil and digest the latest research, ASCO is unmatched in attendance and clinical relevance. Results presented from ongoing trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all cancer medicine. Despite the importance of the conference, the demands of routine practice often limit the amount of time oncology clinicians can realistically dedicate to travel and learning. To bridge the gap between research and patient care, this CME activity will deliver a review of the key presentations from the ASCO Annual Meeting and expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for diverse forms of cancer.

LEARNING OBJECTIVE

- Evaluate emerging Phase III clinical data with the JAK1/2 inhibitor ruxolitinib, and consider this information for the clinical care of patients with myelofibrosis.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides. To receive credit, the participant should review the slide presentations, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/SMJCA2011/Myelofibrosis/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation and Genentech BioOncology.

Last review date: September 2011
Expiration date: September 2012
To go directly to the slides and investigator commentary for the featured abstracts, click here.

An oncology specialist would be hard pressed to find a better hour of television than the first half of the oral leukemia/myelodysplasia plenary session from ASCO 2011. This riveting segment of the conference, available for your viewing pleasure as part of the virtual meeting, began with 2 complementary presentations of Phase III trials evaluating the JAK1/2 inhibitor ruxolitinib (ab 6500, ab LBA6501) in patients with myelofibrosis. These were followed by a fascinating BCR-ABL mutation analysis from the ENESTnd CML study (ab 6502) comparing nilotinib to imatinib and then a brilliant follow-up discussion by Dr Ross Levine outlining a new paradigm in myeloproliferative disorders focused on the search for mutations and related novel blocking agents. These 3 presentations and 14 other compelling ASCO heme-onc data sets are detailed in our slide sets and profiled below in this, the second half of our super-succinct special edition 5-Minute Journal Club.

1. Ruxolitinib in myelofibrosis
As mentioned above, this trial duet occupies a unique spot on the ASCO highlights reel, and while our understanding of the exact mechanism of action of this oral TKI may be somewhat hazy and may relate to reduction in elevated cytokine levels, what is crystal clear is that this uncommon but merciless disease has instantly entered a new era. The US-based COMFORT-I study evaluating ruxolitinib versus placebo had a number of interesting and innovative features, including the use of MRI to objectively evaluate spleen size and electronic daily diaries to record patient symptoms. The dramatic waterfall plots visibly illustrate how treatment at least temporarily reversed an otherwise downhill course in most patients.

2. CML
Dr Giuseppe Saglio presented the other previously discussed ASCO standout — the landmark substudy from the ENESTnd trial (ab 6502) demonstrating that prior to treatment patients had almost no BCR-ABL mutations but after therapy a fascinating panoply of alterations was observed in some individuals. Dr Levine predicted that in the near future, mutation assays will be regularly integrated into the treatment algorithm.
Additionally, 24-month follow-up from 2 key Phase III studies (ENESTnd [ab 6511] and DASISION [ab 6510]) was also unveiled in Chicago, suggesting greater efficacy and perhaps less toxicity with up-front treatment with the second-generation TKIs nilotinib and dasatinib when compared to imatinib.

3. Inotuzumab ozogamicin (our vote for name of the year)
This antibody-drug conjugate in the lineage of brentuximab vedotin in lymphoma and T-DM1 in HER2-positive breast cancer links an anti-CD22 antibody to a cytotoxic agent from the calicheamicins class (runner up). The ASCO findings (ab 6507) in relapsed/refractory ALL demonstrated some type of CR in 61% of patients.

4. Myeloma
For more than a year we have witnessed the evolution of data from 2 major trials (CALGB, French IFM group) demonstrating an impressive delay in disease progression but the suggestion of an increased risk of second primary cancers (SPC) with 2 years of lenalidomide maintenance following stem cell transplant (SCT). At ASCO, 3 additional reports (ab 8007, ab 8008, ab 8009) have for the moment reinforced the concept that if there is an SPC signal it is relatively modest in magnitude and far outweighed by the antimyeloma benefit of maintenance len.

The other much-discussed myeloma paper was a landmark Italian study (ab 8020) that for the first time evaluated the role of autologous SCT in the era of novel antimyeloma agents. A progression-free survival benefit was reported with SCT, but other maturing studies are evaluating this important question.

5. CLL
Maybe the most exciting development in B-cell neoplasm research is the rapid evolution of small molecules that block B-cell receptor signaling, and at ASCO we saw more to be optimistic about with a report on the Bruton’s tyrosine kinase inhibitor PCI-32765 in CLL. In this Phase Ib/II single-agent study (ab 6508), response rates in excess of 50% were observed with minimal toxicity.

6. Diffuse large B-cell lymphoma
The lack of progress in this common cancer since the introduction of rituximab was highlighted again this year with 1 trial failing to show an advantage with dose-dense R-CHOP (ab 8000) and another showing no important survival benefit to consolidation autotransplant after R-CHOP induction (ab 8001).

7. AML
AML in the elderly — a true clinical conundrum — was the subject of 3 underwhelming ASCO reports. The first (ab 6503) showed a modest benefit that was counterbalanced by a relatively high early mortality rate when clofarabine was combined with Ara-C. The
second (ab 6504) demonstrated a modest benefit for decitabine, but discussant Dr Gail Roboz verbalized hope that better outcomes might be observed in her ongoing trial evaluating 10 days of decitabine combined with the proteasome inhibitor bortezomib. The third study (ab 6505) was a Phase I effort evaluating a sequential regimen of azacitidine and lenalidomide that resulted in CRs in 7 of 16 patients.

Finally, we saw another interesting AML study perhaps suggesting a new model for the real-time personalized treatment of the disease. In this Phase I/II trial (ab 6506), the MEK1/2 inhibitor GSK1120212 was shown to have specific activity in patients with RAS mutations.

Coming soon, an online quintet of virtual presentations delving into new developments in non-small cell lung cancer.

Neil Love, MD
Research To Practice
Miami, Florida
A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis

Presentations discussed in this issue

Verstovsek S et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). *Proc ASCO* 2011;Abstract 6500.

Harrison CN et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). *Proc ASCO* 2011;Abstract LBA6501.

Slides from a presentation at ASCO 2011

Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Harrison CN et al.
*Proc ASCO* 2011;Abstract LBA6501.
COMFORT-II: Phase III Trial of JAK1/JAK2 Inhibitor Ruxolitinib versus BAT

- Randomized, open-label, multicenter Phase III trial
- Patients were stratified based on baseline IPSS risk category

Patients with PMF, PPV-MF, or PET-MF with ≥2 IPSS risk factors
N = 219

Randomize
2:1

INC424 (ruxolitinib)
15 or 20 mg oral BID
n = 146

Best available therapy (BAT)
n = 73

Ruxolitinib crossover and extension phase

- Progression events that qualified for the crossover and extension phase:
  - Splenectomy
  - Progressive splenomegaly as defined by a 25% increase in spleen volume compared with the on-study nadir (including baseline)

Harrison CN et al. Proc ASCO 2011;Abstract LBA6501.

Patients with ≥35% Decrease in Spleen Volume at Weeks 24 and 48

**Primary Endpoint**

<table>
<thead>
<tr>
<th>% with ≥35% spleen volume reduction</th>
<th>Ruxolitinib</th>
<th>BAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 48</td>
<td>28.5% n = 41</td>
<td>0</td>
</tr>
</tbody>
</table>

**Key Secondary Endpoint**

<table>
<thead>
<tr>
<th>% with ≥35% spleen volume reduction</th>
<th>Ruxolitinib</th>
<th>BAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 24</td>
<td>31.9% n = 46</td>
<td>0</td>
</tr>
</tbody>
</table>

- Median time to response = 12.29 weeks
- Of patients (n = 69) who achieved ≥35% reduction in spleen volume at any time during the study, 64% (n = 44) did so at the first assessment (at 12 weeks)

With permission from Harrison CN et al. Proc ASCO 2011;Abstract LBA6501.
Percent Change in Spleen Volume from Baseline

Ruxolitinib $p < 0.0001$

Best response at any time on study

<table>
<thead>
<tr>
<th></th>
<th>Ruxolitinib</th>
<th>BAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓ Spleen volume</td>
<td>132 (97%)</td>
<td>35 (56%)</td>
</tr>
<tr>
<td>↑ Spleen volume</td>
<td>4 (3%)</td>
<td>28 (44%)</td>
</tr>
</tbody>
</table>

With permission from Harrison CN et al. Proc ASCO 2011;Abstract LBA6501.

Duration of Spleen Volume Reduction

- Patients achieving ≥35% spleen volume reduction at any time on study: 47.9%
- Median duration of reduction was not reached: 79.7% of patients still responding

* Event: <35% reduction from baseline and ≥25% increase from nadir

With permission from Harrison CN et al. Proc ASCO 2011;Abstract LBA6501.
Change in EORTC QLQ-C30 Scores at Week 48 Compared to Baseline

- Improvements were seen by week eight and continued through week 48.

With permission from Harrison CN et al. Proc ASCO 2011;Abstract LBA6501.

Additional Secondary Endpoints

<table>
<thead>
<tr>
<th></th>
<th>Ruxolitinib (n = 146)</th>
<th>BAT (n = 73)</th>
<th>Hazard ratio</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progression-free survival</td>
<td>70%</td>
<td>74%</td>
<td>0.81</td>
<td>0.46</td>
</tr>
<tr>
<td>Leukemia-free survival</td>
<td>96%</td>
<td>95%</td>
<td>0.65</td>
<td>0.51</td>
</tr>
<tr>
<td>Overall survival</td>
<td>96%</td>
<td>95%</td>
<td>0.70</td>
<td>0.58</td>
</tr>
</tbody>
</table>

Harrison CN et al. Proc ASCO 2011;Abstract LBA6501.
# Hematology Laboratory Values
(Worst Lab Grade on Study**

<table>
<thead>
<tr>
<th></th>
<th>Grade 1 (%)</th>
<th>Grade 2 (%)</th>
<th>Grade 3 (%)</th>
<th>Grade 4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hemoglobin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruxolitinib (n = 146)</td>
<td>16</td>
<td>38</td>
<td>34</td>
<td>8</td>
</tr>
<tr>
<td>BAT (n = 70)</td>
<td>23</td>
<td>40</td>
<td>21</td>
<td>10</td>
</tr>
<tr>
<td><strong>Platelet count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruxolitinib (n = 146)</td>
<td>32</td>
<td>28</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>BAT (n = 69)</td>
<td>16</td>
<td>6</td>
<td>4</td>
<td>3</td>
</tr>
</tbody>
</table>

* Occurring on the randomized treatment phase only
† Percentage is based on baseline total n

- The majority of patients (63% ruxolitinib, 67% BAT) had Grade 1 or 2 anemia at baseline.
- In both arms, all patients who entered the study had ≤ Grade 1 thrombocytopenia at baseline.

Harrison CN et al. Proc ASCO 2011; Abstract LBA6501.

---

# Select Nonhematologic Adverse Events

<table>
<thead>
<tr>
<th></th>
<th>Ruxolitinib (n = 146)</th>
<th>BAT (n = 73)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any grade</td>
<td>Grade 3 or 4</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>23%</td>
<td>1%</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>22%</td>
<td>0%</td>
</tr>
<tr>
<td>Asthenia</td>
<td>16%</td>
<td>1%</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>16%</td>
<td>1%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>15%</td>
<td>0%</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>14%</td>
<td>2%</td>
</tr>
<tr>
<td>Nausea</td>
<td>13%</td>
<td>1%</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>12%</td>
<td>1%</td>
</tr>
<tr>
<td>Cough</td>
<td>13%</td>
<td>0%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>12%</td>
<td>1%</td>
</tr>
</tbody>
</table>

Harrison CN et al. Proc ASCO 2011; Abstract LBA6501.
Conclusions

- The study met its primary and key secondary endpoints with statistical significance.
- Ruxolitinib demonstrated significant and sustained improvement in splenomegaly, disease-related symptoms, functioning and quality of life.
- BAT-treated patients experienced progressive splenomegaly and either no change or worsening of symptoms.
- The safety profile of ruxolitinib was acceptable relative to the control.
- The data extend the positive results of the COMFORT-I trial, which compared ruxolitinib to placebo.
- Data from the COMFORT studies indicate that ruxolitinib has the potential to significantly improve the current treatment landscape for most patients with MF.

Harrison CN et al. *Proc ASCO* 2011;Abstract LBA6501.